key: cord-0924187-xzvl43aa authors: Aladdin, Yasser; Shirah, Bader title: New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine date: 2021-06-07 journal: J Neuroimmunol DOI: 10.1016/j.jneuroim.2021.577629 sha: 6f4643da3764586a7ab5cb430e24ef3e1417f749 doc_id: 924187 cord_uid: xzvl43aa Coronavirus is a novel human pathogen causing fulminant respiratory syndrome (COVID-19). Developing an effective and reliable vaccine was emergently pursued to control the dramatic spread of the global pandemic. The standard stages for vaccine development were unprecedentedly accelerated over a few months. We report a case of new-onset refractory status epilepticus (NORSE) after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. We attribute the occurrence of NORSE to the vaccine due to the temporal relationship and the lack of risk factors for epilepsy in the patient. This report adds to the literature a possible rare side effect of a COVID-19 vaccine and contributes to the extremely limited literature on potential neurological side effects of viral vector vaccines. Healthcare providers should be aware of the possibility of post-vaccination epilepsy. The patient had recurrent seizures that were refractory to conventional antiepileptic drug therapy with a dramatic response to immunotherapy with pulse steroids and plasmapheresis. This likely reflects an underlying autoimmune mechanism in the genesis of post-vaccination generalized seizures without fever. Further research is needed to probe and study the exact mechanism at a more molecular level. Coronavirus is a novel human pathogen causing fulminant respiratory syndrome ) that was first identified in December 2019 as a cluster of cases with fatal pneumonia in Wuhan, China 1 . In March 2020, the World Health Organization declared a worldwide pandemic and designated the disease taxonomy as COVID-19 2 . The disease is an acute severe respiratory syndrome with florid pulmonary manifestations and multiorgan involvement including cardiovascular, musculoskeletal, gastrointestinal, and neurological complications 3 . Developing an effective and reliable vaccine was emergently pursued to control the dramatic spread of the global pandemic. The standard stages for vaccine development were unprecedentedly accelerated over a few months. Inactivated or live-attenuated viruses as well as recombinant proteins and vectors technologies have been employed to develop the COVID-19 vaccine. In addition, new platforms such as RNA and DNA vaccines were also used for the first time in a licensed vaccine 4 . We report a case of new-onset refractory status epilepticus (NORSE) after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. A 42-year-old female nurse of Black South African descent presented to the emergency department complaining of headache and subjective fever that started one day prior. During the assessment, the patient developed a rising epigastric sensation and experienced jamais vu for the first time in her life that rapidly evolved into her first-ever generalized tonic-clonic seizure. She was given 2 mg of lorazepam on two occasions that failed to abort the seizure and was eventually loaded with 1 gram of phenytoin. Her seizure stopped, and she was stabilized and drowsy with post-ictal amnesia. She had no history of fever, infection, or any risk factor for epilepsy. She received the first dose of serology, and vasculitis screen. In addition, cultures from blood, urine, stool, and respiratory secretions were unremarkable. COVID-19 PCR was negative. Brain MRI showed a subtle increase in the signal on FLAIR images at bilateral hippocampi and insula that was correlating with postictal changes (Figure 1 ). The patient was admitted and developed two more episodes of generalized tonic-clonic seizures that were aborted with diazepam. She was started on a loading dose of levetiracetam 1 gram with a maintenance dose of 500 mg twice daily along with phenytoin 100 mg three times daily. The patient continued to have generalized tonic-clonic seizures requiring an increase in levetiracetam dose to 750 mg twice daily and adding lacosamide at 50 mg twice daily. The ChAdOx1 nCoV-19 vaccine is a viral vector vaccine that uses the modified chimpanzee adenovirus ChAdOx1 as a vector 7 . More than 34 million vaccine doses were administered in Europe. The safety profile of the vaccine is good with commonly reported mild side effects such as injection-site pain, nausea, and headache, which usually resolve within a few days 8 . The vaccine was linked to severe thrombotic events secondary to the production of rogue antibodies against platelet factor-4 resulting in massive platelet aggregation leading to cerebral venous sinus thrombosis that could potentially manifest as seizures 9 . Seizures or status epilepticus following this vaccine were not previously reported in the literature. The only speculated mechanism underlying the development of seizures after vaccinations in the literature was a vaccination-induced fever that acts as a seizure trigger 10 . However, our patient was a healthy non-epileptic nurse who developed NORSE as a first presentation only ten days following the first vaccine dose. This makes the fever theory less likely and prompts the search for more integral mechanisms related to the role of pro-inflammatory cytokines in the pathogenesis of post-vaccination epilepsy. Angiotensin-converting enzyme 2 (ACE2) provides the access point of entry for coronaviruses, and ACE2 receptors are present in the brainstem to mediate the regulation vector vaccine may access the cerebral neuronal pathways to replicate the mechanism of seizures in patients with the real COVID-19 infection. The plausible mechanism for seizures is that the inflammatory cascade would conceivably result in neuronal hyperexcitation and subsequent seizures. There is admittedly no biological marker to establish causality between seizures and the modified chimpanzee adenovirus vaccine. However, we cannot ignore the dramatic temporal association between the vaccine and developing a florid status epilepticus in a previously healthy nurse. Moreover, the emergence of NORSE that fails four antiepileptic drugs and necessitating anesthetic agents with dramatic improvement only to autoimmune therapy dictates some respect to the logical thinking of a potential association between seizures and the vaccine. While causality is not confirmed, this case should certainly invoke further research to look for any potential pathogenic mechanism at the molecular level. We report a rare case of NORSE after the first dose of the ChAdOx1 nCoV-19 vaccine. We attribute the occurrence of NORSE to the vaccine due to the temporal relationship and the lack of risk factors for epilepsy in the patient. This report adds to the literature a possible rare side effect of a COVID-19 vaccine and contributes to the extremely limited literature on potential neurological side effects of viral vector vaccines. Healthcare providers should be aware of the possibility of post-vaccination epilepsy. The patient had recurrent seizures that were refractory to conventional antiepileptic drug therapy with a dramatic response to immunotherapy with pulse steroids and plasmapheresis. This likely reflects an underlying autoimmune mechanism in the genesis of post-vaccination generalized seizures without fever. Further research is needed to probe and study the exact mechanism at a more molecular level. A Novel Coronavirus from Patients with Pneumonia in China An interactive web-based dashboard to track COVID-19 in real time Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Coronavirus vaccine development: from SARS and MERS to COVID-19 Covid-19: a global threat to the nervous system How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Thrombosis after covid-19 vaccination How could a COVID vaccine cause blood clots? Scientists race to investigate The potential neurological effect of the COVID-19 vaccines: A review Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan The authors declare that they have no conflicts of interest.